Publications by Ksenya Shchors

Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity

Douglas Hanahan, Krisztian Homicsko, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz, Ksenya Shchors, Julie Laetitia Scotton

Glioblastoma (GBM) is poorly responsive to therapy and invariably lethal. One conceivable strategy to circumvent this intractability is to co-target distinctive mechanistic components of the disease, aiming to concomitantly disrupt multiple capabilities re ...

2022

Deficiency for the Cysteine Protease Cathepsin L Impairs Myc-Induced Tumorigenesis in a Mouse Model of Pancreatic Neuroendocrine Cancer

Douglas Hanahan, Ksenya Shchors, Nicola Rae Brindle

Motivated by the recent implication of cysteine protease cathepsin L as a potential target for anti-cancer drug development, we used a conditional MycER(TAM); Bcl-x(L) model of pancreatic neuroendocrine tumorigenesis (PNET) to assess the role of cathepsin ...

Public Library of Science2015

HG-13SOX9 AS A DOWN-STREAM TARGET IN RAS/MEK-DRIVEN PEDIATRIC GLIOMA

Ksenya Shchors

Oxford, Oxford University Press2015

Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit

Douglas Hanahan, Aristea Massaras, Ksenya Shchors

The associations of tricyclic antidepressants (TCAs) with reduced incidence of gliomas and elevated autophagy in glioma cells motivated investigation in mouse models of gliomagenesis. First, we established that imipramine, a TCA, increased autophagy and co ...

Elsevier2015

Sox9 As A Down-Stream Target In Ras/Mek-Driven Pediatric Glioma

Ksenya Shchors

Oxford Univ Press Inc2015

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy

Douglas Hanahan, Ksenya Shchors, Nan Li

National Academy of Sciences2013

Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis

Douglas Hanahan, Ksenya Shchors

Despite their apparent success in pre-clinical trials, metalloproteinase (MMP) inhibitors proved to be inefficacious in clinical settings. In an effort to understand the underlying causes of this unanticipated outcome, we modeled the consequences of long-t ...

2013